Netherlands· NL-7a3760eaa15e

Bumetanide Sandoz tablet 1, tabletten 1 mg

A bumetanide product containing bumetanide, registered in Netherlands by Sandoz B.V.. The same ATC class is registered in 10 of our 19 countries.

ATC C03CA02

Checked against CBG-MEB (Netherlands) on September 29, 2026

Informational only — not a medical device.

Compare price across countriesPer daily dose · free account Ask the assistant about bumetanideAnswers with sources · free account Check interactionsSeverity free · mechanism on Growth

Where it is registered

Bumetanide is registered in 10 of 19 countries.

Countries holding a registration under ATC C03CA02 (bumetanide), each read from that country’s own register.

This record: Netherlands, from CBG-MEB (Netherlands)
5 of them publish a price we can compare per daily dose

Search bumetanide products by name

Bumetanide · ATC C03CA02

10 / 19 countries

Belgiumprice
Canada
Denmark
Finlandprice
Franceprice
Ireland
Netherlands
Norwayprice
United Kingdom
United Statesprice

Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bumetanide costs, country by country.

Normalised to the WHO defined daily dose (1 mg), so markets compare like for like.

1 market with a comparable price for this class
Public list prices, converted to USD at the rate date shown

Open the full comparison — free account Drug prices for market access

Bumetanide · price per daily dose (1 mg)

USD · FX 28 Sept 2026

FR France$0.13

Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)

Active substance: BUMETANIDE
Manufacturer: Sandoz B.V.
Country: Netherlands (NL)
ATC code: C03CA02
ATC class: Bumetanide
Defined daily dose: 1 mg, O
Reimbursed: Not published by this register
Source register: CBG-MEB (Netherlands)
Last checked: September 29, 2026

Packs & prices · 1

cbg_meb_id
23048

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

318 interactions on record for bumetanide.

Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.

Severity for every pair — free, no plan needed
The source, licence and sync date on every record
Mechanism and what to do for each pair — Growth plan

Check bumetanide against other medicines How interaction checks work

Bumetanide · interactions on record

318 records

15 severe
177 moderate
9 minor
116 info

Most severe, free to view

CisaprideA03FA02severe
DolasetronA04AA04severe
NeomycinA07AA01severe
StreptomycinA07AA04severe

1 more interaction with mechanism and management, from a commercially licensed source.

Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.

Mechanism and what to do, in the interaction check

Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bumetanide in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bumetanide products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

Austria · Burinex
Belgium · Burinex
Denmark · Burinex
Spain · Fordiuran
France · Burinex
United Kingdom (Northern Ireland) · Bumetanide Generics Uk, Bumetanide Niche Generics
Greece · Burinex
Ireland · Burinex
Luxembourg · Burinex
Malta · Burinex
Norway · Burinex
Sweden · Burinex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload

GET /v1/drugs/e16dcff4-499d-43c9-aa35-ca3fc3063bf8
GET /v1/drugs/e16dcff4-499d-43c9-aa35-ca3fc3063bf8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h23048_smpc.pdf",
  "strength": null,
  "atc_label": "Bumetanide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg23048",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "LACTOSE 1-WATER",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "NATRIUMLAURILSULFAAT"
  ],
  "substances": [
    "BUMETANIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h23048.pdf",
  "authorised_at": "1999/03/22",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "23048",
  "additional_monitoring": "N"
}

API reference MCP server Plans

See everything about bumetanide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it free Open in the console